Rigel’s Troubled Arthritis Treatment
Biotehc firm Rigel's (RIGL) rheumatoid arthritis drug candidate R788 did not meet its primary endpoint in Phase IIb clinical trial, probably putting in question the company’s goal of securing ...Read Full Story »



